Integral Health Asset Management, LLC Immuno Gen, Inc. Transaction History

Integral Health Asset Management, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$4.26 - $7.48 $1.07 Million - $1.87 Million	-250,000 Closed	0 $0
Q4 2021 Feb 02, 2022	SELL	$4.75 - $7.5 $237,500 - $375,000	-50,000 Reduced 16.67%	250,000 $1.86 Million
Q3 2021 Nov 12, 2021	BUY	$5.02 - $6.59 $1.51 Million - $1.98 Million	300,000 New	300,000 $1.7 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Integral Health Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Integral Health Asset Management, LLC with notifications on news.